IL28B Genomic-Based Treatment Paradigms for Patients With Chronic Hepatitis C Infection: The Future of Personalized HCV Therapies

Clark, Paul J.; Thompson, Alex J.; McHutchison, John G.
January 2011
American Journal of Gastroenterology;Jan2011, Vol. 106 Issue 1, p38
Academic Journal
Genome-wide association studies (GWAS) have recently identified host genetic variation to be critical for predicting treatment response and spontaneous clearance in patients infected with hepatitis C virus (HCV). These important new studies are reviewed and their future clinical implications discussed. Single-nucleotide polymorphisms in the region of the IL28B gene on chromosome 19, coding for the interferon (IFN)-λ-3 or IL28B gene, are strongly associated with treatment response to pegylated IFN and ribavirin in patients infected with genotype 1 HCV. The good response variant is associated with a twofold increase in the rate of cure. Allele frequencies differ between ethnic groups, largely explaining the observed differences in response rates between Caucasians, African Americans and Asians. IL28B polymorphism is also strongly associated with spontaneous clearance of HCV. The biological mechanisms responsible for these genetic associations remain unknown and are the focus of ongoing research. Knowledge of a patient's IL28B genotype is likely to aid in clinical decision making with standard of care regimens. Future studies will investigate the possibility of individualizing treatment duration and novel regimens according to IL28B type.


Related Articles

  • Clinical utility of pharmacogenomics in the management of hepatitis C. Trinks, Julieta; Hulaniuk, María Laura; Redal, María Ana; Flichman, Diego // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p339 

    Hepatitis C virus (HCV) was identified for the first time more than 20 years ago. Since then, several studies have highlighted the complicated aspects of this viral infection in relation to its worldwide prevalence, its clinical presentation, and its therapeutic response. Recently, two landmark...

  • Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile. Vargas, Constanza L.; Espinoza, Manuel A.; Giglio, Andrés; Soza, Alejandro // PLoS ONE;11/6/2015, Vol. 10 Issue 10, p1 

    Introduction: Daclatasvir and Asunaprevir (DCV/ASV) have recently been approved for the treatment of chronic hepatitis C virus infection. In association, they are more effective and safer than previous available treatments, but more expensive. It is unclear if paying for the additional costs is...

  • Reversion of naturally occurringhigh-level resistance mutations toNS3 protease inhibitors in two treatment-naive individualsinfected with hepatitis C virus. Bagaglio, Sabrina; Messina, Emanuela; Uberti-Foppa, Caterina; Merli, Marco; Torre, Liviana Della; Lazzarin, Adriano; Hasson, Hamid; Morsica, Giulia // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1448 

    A letter to the editor is presented about case reports of two individuals infected with hepatitis C virus.

  • Drug therapy for chronic hepatitis C: An update. NOLAN, RYAN; LAPOINTE, STEPHANIE // Pharmacy Today;April2014, Vol. 20 Issue 4, p54 

    The article discusses the developments in the study for drug therapy on hepatitis C virus (HCV) on patients with chronic hepatitis C diseases in the U.S. It mentions the chronic hepatitis C etiology and course, which primarily infects hepatocytes in human leading to chronic inflammation on the...

  • Patient adherence to therapy for hepatitis C. PATELAROU, E.; BROKALAKI, H.; ELEFSINIOTIS, I.; DOURAKIS, S. // Archives of Hellenic Medicine / Arheia Ellenikes Iatrikes; 

    This is a literature review of the current knowledge regarding compliance with treatment among patients with hepatitis C virus infection. Two researchers performed a Medline search of publications from January 1974 to May 2011 using the key words (Mesh terms): "Medication adherence" or "patient...

  • Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines. Harada, Naoki; Hiramatsu, Naoki; Oze, Tsugiko; Yamada, Ryoko; Kurokawa, Mika; Miyazaki, Masanori; Yakushijin, Takayuki; Miyagi, Takuya; Tatsumi, Tomohide; Kiso, Shinichi; Kanto, Tatsuya; Kasahara, Akinori; Oshita, Masahide; Mita, Eiji; Hagiwara, Hideki; Inui, Yoshiaki; Katayama, Kazuhiro; Tamura, Shinji; Yoshihara, Harumasa; Imai, Yasuharu // Journal of Gastroenterology;Apr2013, Vol. 48 Issue 4, p535 

    Background: This study was conducted to evaluate Japanese treatment guidelines for patients with chronic hepatitis C virus (HCV) infection and normal alanine aminotransferase (N-ALT) levels from the viewpoint of the incidence of hepatocellular carcinoma (HCC). Methods: Four groups of patients...

  • My Treatment Approach to Chronic Hepatitis C Virus. Shiffman, Mitchell L.; Long, April G.; James, Amy; Alexander, Phillip // Mayo Clinic Proceedings;Jul2014, Vol. 89 Issue 7, p934 

    The treatment of chronic hepatitis C virus (HCV) is evolving rapidly. In 2014, the standard of care and new backbone of HCV treatment is the polymerase inhibitor sofosbuvir (SOF). Our treatment approach in patients with HCV genotype 1 is 12 weeks of SOF, peginterferon (PEGINF), and ribavirin...

  • Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes. Graw, Frederik; Balagopal, Ashwin; Kandathil, Abraham J.; Ray, Stuart C.; Thomas, David L.; Ribeiro, Ruy M.; Perelson, Alan S. // PLoS Computational Biology;Nov2014, Vol. 10 Issue 11, p1 

    Chronic liver infection by hepatitis C virus (HCV) is a major public health concern. Despite partly successful treatment options, several aspects of intrahepatic HCV infection dynamics are still poorly understood, including the preferred mode of viral propagation, as well as the proportion of...

  • Medivir's Simeprevir Aces Three Phase III HCV Trials. Sheridan, Cormac // BioWorld Today;12/21/2012, Vol. 23 Issue 247, p1 

    The article focuses on the trials conducted by Medivir AB on simeprevir in patients with hepatitis C virus (HCV). A response-guided treatment (RGT) protocol was followed in all three studies. Research executive Charlotte Edenius explains the efficacy data and notes that the incidence of adverse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics